Polyurethane Excipient Patent Granted to DSM IP Assets

ChangeBridge: Patent Grants - Pharma (A61K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted patent US12589153B2 to DSM IP ASSETS B.V. on March 31, 2026, covering a polyurethane excipient composition for medical devices. The patent claims a catalyst-free polyurethane with specific thermal and molecular weight properties, suitable for drug delivery applications with 18 total claims.

View original document View source feed page

What changed

USPTO granted patent US12589153B2 to DSM IP ASSETS B.V. on March 31, 2026, for a polyurethane excipient composition. The patent covers polyurethanes comprising residues of aliphatic diisocyanate, poly(ethylene oxide) moiety diol, polycarbonate moiety diol, and chain extender, with melting temperature of 140°C or less and molecular weight of 100,000-500,000 g/mol. The composition can be catalyst-free and formed by reactive extrusion for use in medical devices with bioactive agents.

This is a routine patent grant announcement creating no new compliance obligations. Companies developing pharmaceutical coatings, drug delivery systems, or medical device surfaces should review this patent to assess potential freedom-to-operate implications. The 18 claims establish intellectual property protection for DSM's composition and medical device applications.

Source document (simplified)

← USPTO Patent Grants

Polyurethane excipient

Grant US12589153B2 Kind: B2 Mar 31, 2026

Assignee

DSM IP ASSETS B.V.

Inventors

Jennifer Al-Rashid, Jacob Riffey, John Andrew Zupancich

Abstract

In an embodiment, a polyurethane comprises the residues of i. an aliphatic diisocyanate, ii. an aliphatic diol comprising a poly(ethylene oxide) moiety, iii. an aliphatic diol comprising a polycarbonate moiety, and iv. a chain extender, wherein the polyurethane has a melting temperature of 140° C. or less and has a weight average molecular weight of from 100,000 to 500,000 g/mol. In an embodiment, the polyurethane is substantially devoid of catalyst. In an embodiment, the polyurethane is formed by reactive extrusion. In an embodiment, a medical device comprises the polyurethane and a bioactive agent. The medical devices, methods, and polyurethanes may exhibit benefits in end-product biostability, drug release profile, health and safety, and processing speed or reproducibility.